by Nathaniel Harding | Feb 22, 2024 | Blog
A Cortado Conversation with CorriXR Therapeutics CEO Deborah Moorad Cortado is thrilled to invest in CorriXR Therapeutics, an early-stage biotech company commercializing a platform gene editing technology with a first-use case in oncology. The novel approach seeks to...
by Nathaniel Harding | Feb 20, 2024 | Newsletters
Bottom Line Up Front (BLUF) In this month’s Doubleshot Newsletter, you will find: Midcon VC Summit 2024 Cortado News Portco News Ecosystem News & Events Midcon VC Summit 2024 Registration Is Open! The Midcon VC Summit is coming to Bentonville! Join us for...
by Nathaniel Harding | Feb 12, 2024 | Media
Our Principal, Susan Moring, joined CorriXR CEO, Deborah Moorad and CorriXR’s Founder and CSO, Eric B. Kmiec, in an exclusive interview with OETA. This insightful interview highlights the pioneering efforts this amazing company is making in transforming gene editing...
by Nathaniel Harding | Feb 7, 2024 | Media
We are excited to share an exclusive feature published by Axios on Lumata Health on their Series A+ funding round from 2023. We are proud to have one of our spectacular portfolio companies featured in such a reputable publication, and we look forward to continued...
by Nathaniel Harding | Feb 7, 2024 | Media
This article discusses the impact of the Federal Reserve’s decision not to cut interest rates and its implications for various sectors, including venture capital (VC). The Federal Reserve’s indication that rate cuts are unlikely in the near future has led...
